EyePoint Inc

EYPT

Market cap $1.25B

14.93 USD

+0.12

0.81%

At close Updated Apr 17, 4:00 PM EDT

Pre-market

After hours

14.88

-0.05

0.33%

1 day

0.81%

5 days

5.29%

1 month

7.41%

3 months

-3.93%

6 months

28.37%

Year to date

-14.59%

1 year

162.85%

5 years

64.43%

10 years

-51.21%

About: EyePoint Inc focuses is a clinical-stage biopharmaceutical company committed to developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases, that may reduce the frequency of follow-up care. The company's pipeline program includes i) DURAVYU: a sustained-release product candidate for retinal diseases, with the potential to provide patients with improved visual outcomes with less burden. ii) EYP-2301: early-stage program using Durasert E technology to deliver razuprotafib, a TIE-2 agonist targeting VE-PTP for vascular stability in retinal diseases like wet AMD.

Employees: 214

Healthcare Biotechnology